The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.
Paul Barrett, TeleTracking UK, explains how automating patient flow and bed management in real-time can transform hospital operations, free up time for nurses to care, reduce stress on caregivers and importantly improve patient outcomes.
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
Childhood air pollution has been understood as partially responsible for respiratory health - now, researchers are investigating at how exposure can damage cognitive ability later on in life.
According to data collected by 400 healthcare professionals at the worst moment of the US outbreak, the life support machine that acts in place of the heart and lungs is crucial to reducing COVID-19 deaths for the critically ill.
An STFC-funded project, MoleGazer, has successfully implemented astronomical techniques, used for star-gazing, to detect and track the evolution of cancerous moles.
A professor describes severe maternal morbidity in low-income women as a public health crisis - now, Medicaid expansion seems to be improving pregnancy outcomes.
New clinical trial data shows that the Johnson & Johnson vaccine is able to give 66% protection against COVID in one dose - with an 85% efficiency at the standard double-dose.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
Hugh Bettesworth, CEO, Mirada Medical, explores how AI autocontouring technology can help tackle the cancer care backlog as a result of the COVID-19 pandemic.
New data from the REACT study finds that the rising infection rate has steadied a little, but there is no "sharp drop in infections" as in the first wave and the R is still high.
The company announced that their current vaccine can handle the South African COVID mutation - with plans to create an "additional booster dose" to see if they can create specific protections against emerging variants.
